Since GlycoMimetics Inc. (NASDAQ:GLYC) and AquaBounty Technologies Inc. (NASDAQ:AQB) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation of both companies.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlycoMimetics Inc.	N/A	0.00	48.27M	-1.13	0.00
AquaBounty Technologies Inc.	N/A	573.31	12.20M	-0.93	0.00

Table 1 highlights GlycoMimetics Inc. and AquaBounty Technologies Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

	Net Margins	Return on Equity	Return on Assets
GlycoMimetics Inc.	0.00%	-21.7%	-20.9%
AquaBounty Technologies Inc.	0.00%	-47.2%	-38.8%

Liquidity

GlycoMimetics Inc. has a Current Ratio of 34.6 and a Quick Ratio of 34.6. Competitively, AquaBounty Technologies Inc.’s Current Ratio is 1 and has 0.9 Quick Ratio. GlycoMimetics Inc.’s better ability to pay short and long-term obligations than AquaBounty Technologies Inc.

Analyst Recommendations

GlycoMimetics Inc. and AquaBounty Technologies Inc. Recommendations and Ratings are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
GlycoMimetics Inc.	0	0	1	3.00
AquaBounty Technologies Inc.	0	0	0	0.00

GlycoMimetics Inc.’s upside potential is 91.03% at a $23 consensus target price.

Insider & Institutional Ownership

GlycoMimetics Inc. and AquaBounty Technologies Inc. has shares owned by institutional investors as follows: 0% and 67.2%. 0.2% are GlycoMimetics Inc.’s share owned by insiders. On the other hand, insiders owned about 1.1% of AquaBounty Technologies Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
GlycoMimetics Inc.	-2.13%	6.43%	-1.65%	-20.74%	-49.3%	25.87%
AquaBounty Technologies Inc.	-10.61%	0.92%	-11.69%	-26.01%	-7.59%	6.83%

For the past year GlycoMimetics Inc. has stronger performance than AquaBounty Technologies Inc.

Summary

GlycoMimetics Inc. beats AquaBounty Technologies Inc. on 5 of the 8 factors.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

AquaBounty Technologies, Inc., a biotechnology company, develops and markets products to enhance productivity in aquaculture. Its lead product is the AquAdvantage Salmon, a genetically modified animal for human consumption. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was founded in 1991 and is headquartered in Maynard, Massachusetts. AquaBounty Technologies, Inc. is a subsidiary of Intrexon Corporation.